Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma

Our findings highlight the prognostic value of post-surgical, personalized ctDNA detection of recurrence and longitudinal disease surveillance in stage I-IIIB melanoma. The impact of ctDNA on real-world clinical decision-making highlights the need to assess outcomes when cancer management is influenced by ctDNA dynamics.